Namieta M. Janssen

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

Mark C. Genovese, Roy Fleischmann, Daniel E. Furst et al. · Annals of the Rheumatic Diseases · 2014 · 141 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus

Javier P. Berrios-Rivera, Richard L. Street, Maria G. Garcia Popa‐lisseanu et al. · Arthritis Care & Research · 2006 · 136 citations

Social Sciences, Communication, Internal Medicine +17

Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus

Araceli García-González, Marsha Richardson, Maria G. Garcia Popa‐lisseanu et al. · Clinical Rheumatology · 2008 · 133 citations

Medicine, Internal Medicine, Pharmacotherapy +15

Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease.

Maria G. Garcia Popa‐lisseanu, Anthony Greisinger, Marsha Richardson et al. · 商学論究 · 2005 · 129 citations

Public Health, Clinical Sciences, Health Equity +16